n n n ‘. concat(e. i18n. t(“search. voice. recognition_retry”),’n
JUPITER, Fla. , Nov. 20, 2023 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic,” “we,” “us,” “our,” or the “Company”) (NASDAQ: DYAI), a company global biotechnology company focused on building cutting-edge microbial protein production platforms to meet growing demand for global protein biomanufacturing and unmet clinical desires for effective biopharmaceuticals, Dear Dyadic, an offshore innovator for affordable human and animal health and available, the firm applauded today. of an agreement between Dyadic’s African licensee, Rubic One Health (“Rubic”) and Afreximaxbank to finance the transfer of vaccine pre-production facilities to Dyadic’s C1 protein production platform in South Africa for the entire continent.
In April 2023, Dyadic expanded its licensing agreement with Rubic, a South African company whose project is to develop solutions in Africa for the discovery, expansion, evaluation and production of high-quality, cost-effective human and animal vaccines and therapeutics. Dyadic’s C1 expression platform for distribution primarily in the African market. The quest to produce affordable vaccines suitable for humans and animals in Africa has moved one step closer to achieving this with the signing of the agreement between Rubic and Afreximaxbank.
“We are very pleased that Rubic has secured resources to drive the progression of vaccines and biologics critical to human and animal fitness, as part of its project to expand a comprehensive solution for vaccines and biologics that closes the important fitness gap. . in Africa. ” said Mark Emalfarb, president and CEO of Dyadic. “”In addition to taking a step forward in offering affordable vaccine and antibody responses to the African continent, we expect this agreement to also expand potential commercialization opportunities for multiple animal and human fitness products, the company’s patented and patented C1 platform. company.
Mr. Emalfarb continued, “Dyadic’s agreement with Rubic includes an equity stake in Rubic and royalties on individual products upon commercialization. Dyadic reserves the right to market the vaccines and therapeutics for human and animal health developed through Rubic outside the African continent. We plan to expand our appointments with Rubic to include vaccines and biologics against infectious diseases and other key spaces beyond COVID, such as HIV and cancer, our proprietary and proprietary C1 protein expression platform.
“Africa imports about 96% of its vaccines and has very limited production capacity. We learned early on in the COVID-19 pandemic that there were significant vaccine inequalities in Africa and that we were at the mercy of large pharmaceutical corporations and developed countries. “This historic agreement with Afreximaxbank to finance the Vaccine Manufacturing Preparatory Facility Project has the prospect of delivering affordable vaccines to Africans by Africans, which is now one step closer to reality,” said Dr. Julian Naidoo, CEO of Rubic One Health. Array Dr Naidoo continued: “We intend to use this investment to address this market failure by gaining better access to locally manufactured vaccines and medicines through our licensing agreement with Dyadic. , its C1 fungal expression formula for the progression and manufacturing of vaccines for animals and humans. Vaccines and therapeutics. Through our collaboration with Dyadic, we hope to bring high-demand, safe, effective and affordable vaccines to the African continent, more suitable for African situations as they do not require production or storage in ultra-cold temperatures and can be distributed safely. security in remote and rural areas of the African continent. This is a turning point in vaccine production for Africans,” Dr Naidoo concluded.
About Rubic One Health
Rubic One Health is comprised of allocation sponsors representing the public sectors of health, medicine, academia, vaccine generation, generation transfer, and economy. The progression and implementation of vaccine technologies is overseen through leading educators led by the University of the Witwatersrand in Johannesburg (Wits) education team, with the Wits Health Consortium (WHC), a wholly-owned company of Wits. The Consortium collectively has extensive experience in the fields of vaccinology, public health medicine, clinical trials, research, generation transfer, allocation control and fitness economics. This entity will coordinate the task, ensuring synergistic end results between the drug discovery/research and production components. It will also determine the strategic and operational direction. This will be complemented by the involvement of stakeholders and public fitness experts. and education to ensure that the company moves forward in a way that is sustainable, Afrocentric, and rooted in the public good. Visit Rubic’s online page on https://www. rubiconefitness. co. za for more information. .
About Dyadic International, Inc.
Dyadic International, Inc. es a global biotechnology company whose goal is to create cutting-edge microbial platforms to meet the growing demand for global protein bioproduction and the unmet clinical desires for effective biopharmaceuticals available for human and animal fitness.
Dyadic’s gene expression and protein production platforms are based on the highly productive and evolving fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Our flagship technology, the C1 cellular protein production platform, is based on an industrially displayed microorganism (called C1), which is lately used to drive progress, reduce production prices, and the functionality of vaccines and biologics at commercially flexible scales for human and animal health markets. Dyadic has also developed the DapibusTM filamentous fungus-based microbial protein production platform to enable immediate progression and large-scale production of inexpensive proteins, metabolites, and other biologics for use in non-pharmaceutical applications, such as food, nutrition, and wellness.
With a hobby that will enable our partners and collaborators to expand effective preventive and curative remedies in evolved and emerging countries, Dyadic is building an active pipeline by advancing its proprietary microbial platform technologies, adding our core asset, COVID-19 vaccine candidate DYAI-100. , as well as other biological products, antibodies and other biological products.
To learn more about Dyadic and our commitment to bringing vaccines and other biologics to market faster, in higher volumes and at lower costs, visit http://www. dyadic. com.
Safe Harbor Regarding Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic’s international expectations, intentions, methods and ideals. regarding long-term events. or long-term occasions. monetary performance, such as the good fortune of our clinical trial, study projects and collaborations with third parties, as well as the availability of mandatory financing. Actual events or effects could differ materially from those indicated in the forward-looking statements due to important points, other than those described in the Company’s most recent filings with the SEC. Dyadic undertakes no legal responsibility to publicly update any such forward-looking statements, whether as a result of new information, long-term developments or otherwise. For a more complete description of hazards that could also cause our actual effects to differ from our existing expectations, please see the segment titled “Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-K. Form 10-Q filed. with the SEC, as those items may be updated from time to time in Dyadic’s periodic filings with the SEC, which are located on the SEC’s online website and at www. dyadic. com.
Contact:
Dyadic International, Inc. Ping W. Rawson Chief Financial Officer Phone: (561) 743-8333 Email: ir@dyadic. com